24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms.

          Related collections

          Author and article information

          Journal
          Ann. Oncol.
          Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
          1569-8041
          0923-7534
          Dec 2015
          : 26
          : 12
          Affiliations
          [1 ] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore jarushka_14@yahoo.com.
          [2 ] Providence Portland Medical Center and Earl A. Chiles Research Institute, Portland.
          [3 ] Department of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA.
          [4 ] Department of Dermatology, Medical University of Vienna, Vienna, Austria.
          [5 ] Dermatology Service, Memorial Sloan Kettering Cancer Center, New York Department of Medicine, Weill Cornell Medical College, New York, USA.
          [6 ] Department of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA Department of Medicine, Weill Cornell Medical College, New York, USA.
          Article
          mdv383
          10.1093/annonc/mdv383
          26371282
          2e2f877d-cb53-4652-bb04-92ee1e4eaf1c
          © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
          History

          adverse event,anti-PD-1,anti-PD-L1,immune checkpoint antibody,toxicity

          Comments

          Comment on this article